Technical Analysis for VNDA - Vanda Pharmaceuticals Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 4.59 | 2.46% | 0.11 |
Earnings due: May 1
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 2.46% | |
| Fell Below 200 DMA | Bearish | 2.46% | |
| MACD Bearish Signal Line Cross | Bearish | 2.46% | |
| Calm After Storm | Range Contraction | 2.46% | |
| Narrow Range Bar | Range Contraction | 2.46% | |
| Wide Bands | Range Expansion | 2.46% | |
| Down 3 Days in a Row | Weakness | 2.46% | |
| Down 4 Days in a Row | Weakness | 2.46% | |
| Calm After Storm | Range Contraction | 0.66% | |
| Narrow Range Bar | Range Contraction | 0.66% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 2 hours ago |
| Up 3% | about 2 hours ago |
| 20 DMA Resistance | about 5 hours ago |
| Rose Above Previous Day's High | about 5 hours ago |
| Rose Above 20 DMA | about 5 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/01/2024
Vanda Pharmaceuticals Inc. Description
Vanda Pharmaceuticals, Inc., a biopharmaceutical company, offers development and commercialization of products for the treatment of central nervous system disorders. The company provides Fanapt, a compound for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist that has indications for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, alcohol dependence, anxiety, depression, and pruritus. Its product in clinical development includes Tasimelteon, which completed Phase III clinical trials for the treatment of circadian rhythm sleep disorders, as well as completed Phase IIb/III trials for the treatment of major depressive disorder and insomnia. Vanda Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Washington, District of Columbia.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Alcohol Oncology Organic Compounds Chemical Compounds Chemotherapy Schizophrenia Central Nervous System Disorders Depression Major Depressive Disorder Nervous System Disorders Depressive Disorder Sleep Disorders Pyridines Treatment Of Major Depressive Disorder Insomnia Nausea Sedatives Treatment Of Schizophrenia Treatment Of Central Nervous System Disorders Pruritus Chemotherapy Induced Nausea Fanapt Iloperidone
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.0 |
| 52 Week Low | 3.295 |
| Average Volume | 2,569,802 |
| 200-Day Moving Average | 4.48 |
| 50-Day Moving Average | 4.27 |
| 20-Day Moving Average | 4.52 |
| 10-Day Moving Average | 4.60 |
| Average True Range | 0.33 |
| RSI (14) | 50.98 |
| ADX | 32.15 |
| +DI | 40.40 |
| -DI | 22.99 |
| Chandelier Exit (Long, 3 ATRs) | 5.05 |
| Chandelier Exit (Short, 3 ATRs) | 4.84 |
| Upper Bollinger Bands | 5.31 |
| Lower Bollinger Band | 3.73 |
| Percent B (%b) | 0.48 |
| BandWidth | 35.00 |
| MACD Line | 0.15 |
| MACD Signal Line | 0.15 |
| MACD Histogram | -0.0033 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.69 | ||||
| Resistance 3 (R3) | 4.70 | 4.63 | 4.66 | ||
| Resistance 2 (R2) | 4.63 | 4.58 | 4.63 | 4.64 | |
| Resistance 1 (R1) | 4.56 | 4.55 | 4.53 | 4.55 | 4.63 |
| Pivot Point | 4.49 | 4.49 | 4.48 | 4.49 | 4.49 |
| Support 1 (S1) | 4.42 | 4.44 | 4.39 | 4.41 | 4.33 |
| Support 2 (S2) | 4.35 | 4.41 | 4.35 | 4.32 | |
| Support 3 (S3) | 4.28 | 4.35 | 4.31 | ||
| Support 4 (S4) | 4.27 |
